Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,544
archived clinical trials in
Ovarian Cancer

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated:  11/16/2017
Site Reference ID/Investigator# 117320
mi
from
Groningn,
A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated: 11/16/2017
Site Reference ID/Investigator# 117320
mi
from
Groningn,
Click here to add this to my saved trials
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
A Phase I/II Study of Intravenous Doxil and Intraperitoneal Carboplatin as Salvage Therapy in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  11/16/2017
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
A Phase I/II Study of Intravenous Doxil and Intraperitoneal Carboplatin as Salvage Therapy in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 11/16/2017
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)
Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial.
Status: Enrolling
Updated:  11/20/2017
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)
Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial.
Status: Enrolling
Updated: 11/20/2017
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated:  11/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated: 11/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated:  11/20/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated: 11/20/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated:  11/20/2017
University Health Network-Princess Margaret Hospital
mi
from
Toronto,
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer
A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease
Status: Enrolling
Updated: 11/20/2017
University Health Network-Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated:  11/22/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated: 11/22/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated:  11/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated: 11/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated:  11/22/2017
Mass General/North Shore Cancer Center
mi
from
Danvers, MA
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated: 11/22/2017
Mass General/North Shore Cancer Center
mi
from
Danvers, MA
Click here to add this to my saved trials
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated:  11/22/2017
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated: 11/22/2017
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated:  11/22/2017
VA Boston Healthcare System
mi
from
Boston, MA
Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status: Enrolling
Updated: 11/22/2017
VA Boston Healthcare System
mi
from
Boston, MA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Evanston, IL
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Asheville, NC
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Bismarck, ND
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Sioux Falls, SD
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Annandale, VA
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Annandale, VA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Los Angeles, CA
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
San Francisco, CA
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Norwalk, CT
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Norwalk, CT
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Stamford, CT
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Orlando, FL
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Tampa, FL
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
New York, NY
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Durham, NC
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Abington, PA
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Abington, PA
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Fort Sam Houston, TX
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
San Antonio, TX
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Green Bay, WI
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Milwaukee, WI
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
West Allis, WI
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
West Allis, WI
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Research Site
mi
from
New Lambton Heights,
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Research Site
mi
from
New Lambton Heights,
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Saint Louis Park, MN
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  11/27/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 11/27/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase I Study of Weekly Topotecan in Women With Progressive or Recurrent Ovarian Cancer and a Poor Performance Status
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase I Study of Weekly Topotecan in Women With Progressive or Recurrent Ovarian Cancer and a Poor Performance Status
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
Status: Enrolling
Updated:  11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)
Status: Enrolling
Updated: 11/27/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers
Status: Enrolling
Updated:  11/28/2017
University of Washington School of Medicine
mi
from
Seattle, WA
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers
Status: Enrolling
Updated: 11/28/2017
University of Washington School of Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Medical Center of Aurora
mi
from
Aurora, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Medical Center of Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Boulder Community Hospital
mi
from
Boulder, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rocky Mountain Cancer Centers - Boulder
mi
from
Boulder, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rocky Mountain Cancer Centers-Penrose
mi
from
Colorado Springs, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rocky Mountain Cancer Centers-Penrose
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rose Medical Center
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rocky Mountain Cancer Centers - Midtown
mi
from
Denver, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Rocky Mountain Cancer Centers-Rose
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Rocky Mountain Cancer Centers-Rose
mi
from
Denver, CO
Click here to add this to my saved trials
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated:  11/29/2017
Porter Adventist Hospital
mi
from
Denver, CO
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Status: Enrolling
Updated: 11/29/2017
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials